PE20240817A1 - Mutantes de proteina f de rsv - Google Patents

Mutantes de proteina f de rsv

Info

Publication number
PE20240817A1
PE20240817A1 PE2023001148A PE2023001148A PE20240817A1 PE 20240817 A1 PE20240817 A1 PE 20240817A1 PE 2023001148 A PE2023001148 A PE 2023001148A PE 2023001148 A PE2023001148 A PE 2023001148A PE 20240817 A1 PE20240817 A1 PE 20240817A1
Authority
PE
Peru
Prior art keywords
protein
rsv
mutant
polypeptide
subtype
Prior art date
Application number
PE2023001148A
Other languages
English (en)
Inventor
Ye Che
Philip Ralph Dormitzer
Alexey Vyacheslavovich Gribenko
Luke David Handke
Avvari Krishna Prasad
Xiayang Qiu
Mark Edward Ruppen
Xi Song
Kena Anne Swanson
Srinivas Kodali
Xin Xu
KariAnn Sweeney Efferen
Ping Cai
Kristin Rachael Tompkins
Lorna del Pilar Nunez
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of PE20240817A1 publication Critical patent/PE20240817A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/22—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a Strep-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/735—Fusion polypeptide containing domain for protein-protein interaction containing a domain for self-assembly, e.g. a viral coat protein (includes phage display)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18522—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18571—Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La presente invencion se refiere a mutantes de una proteina F de RSV de tipo silvestre y del subtipo A o B, los cuales comprenden un polipeptido F1 y F2 y mutaciones de aminoacidos introducidas relativas a la proteina F de RSV de tipo silvestre, por ejemplo, un par de mutaciones de cisteina que consiste en: 103C y 148C. Asimismo, las posiciones de los aminoacidos de esta proteina estan numeradas de acuerdo a la SEQ ID NO: 1. Tambien, refiere a los usos de moleculas de acido nucleico y vectores que codifican a los presentes mutantes y composiciones farmaceuticas, que comprenden un primer y segundo mutante, en donde el extremo C-terminal del polipeptido F1 del primer mutante de la proteina F del RSV de subtipo A y el extremo C-terminal del polipeptido F1 del segundo mutante de la proteina F del RSV de subtipo B, esta cada uno enlazado a un dominio plegado de fibritina del fago T4.
PE2023001148A 2015-12-23 2016-12-09 Mutantes de proteina f de rsv PE20240817A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562387270P 2015-12-23 2015-12-23
US201662421184P 2016-11-11 2016-11-11
PCT/IB2016/057502 WO2017109629A1 (en) 2015-12-23 2016-12-09 Rsv f protein mutants

Publications (1)

Publication Number Publication Date
PE20240817A1 true PE20240817A1 (es) 2024-04-18

Family

ID=57590746

Family Applications (3)

Application Number Title Priority Date Filing Date
PE2018001128A PE20181354A1 (es) 2015-12-23 2016-12-09 Mutantes de proteina f de rsv
PE2023001147A PE20232039A1 (es) 2015-12-23 2016-12-09 Mutantes de proteina f de rsv
PE2023001148A PE20240817A1 (es) 2015-12-23 2016-12-09 Mutantes de proteina f de rsv

Family Applications Before (2)

Application Number Title Priority Date Filing Date
PE2018001128A PE20181354A1 (es) 2015-12-23 2016-12-09 Mutantes de proteina f de rsv
PE2023001147A PE20232039A1 (es) 2015-12-23 2016-12-09 Mutantes de proteina f de rsv

Country Status (18)

Country Link
US (5) US9950058B2 (es)
EP (1) EP3393512A1 (es)
JP (4) JP6817307B2 (es)
KR (3) KR20230035429A (es)
CN (1) CN108738312A (es)
AU (4) AU2016379097C1 (es)
BR (1) BR112018010805A2 (es)
CA (2) CA3217696A1 (es)
CO (1) CO2018006301A2 (es)
IL (2) IL311990A (es)
MX (2) MX2018007622A (es)
PE (3) PE20181354A1 (es)
PH (1) PH12018501355A1 (es)
RU (1) RU2723039C2 (es)
SA (1) SA518391839B1 (es)
SG (2) SG11201804148TA (es)
TW (4) TWI707866B (es)
WO (1) WO2017109629A1 (es)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6685903B2 (ja) 2013-07-25 2020-04-22 アバター・メディカル・エルエルシー 立体構造的に安定化されたｒｓｖ融合前ｆタンパク質
US9630994B2 (en) 2014-11-03 2017-04-25 University Of Washington Polypeptides for use in self-assembling protein nanostructures
RU2019130167A (ru) 2017-04-04 2021-05-05 Юниверсити Оф Вашингтон Самосборные белковые наноструктуры, экспонирующие f-белки парамиксовируса и/или пневмовируса, и их применение
EP3664836A4 (en) 2017-08-07 2021-05-19 Calder Biosciences Inc. PRE-FUSION RSV PRE-FUSION STABILIZED IN TERMS OF CONFORMITY
WO2019147749A2 (en) * 2018-01-29 2019-08-01 Merck Sharp & Dohme Corp. Stabilized rsv f proteins and uses thereof
EP3758747A1 (en) 2018-02-28 2021-01-06 University of Washington Self-asssembling nanostructure vaccines
MX2021001479A (es) 2018-08-07 2021-04-28 Glaxosmithkline Biologicals Sa Novedosos procesos y vacunas.
JOP20210106A1 (ar) * 2018-11-13 2023-01-30 Janssen Vaccines And Prevention B V بروتينات rsv f سابقة الاندماج مستقرة
US11629172B2 (en) 2018-12-21 2023-04-18 Pfizer Inc. Human cytomegalovirus gB polypeptide
CN110054668B (zh) * 2019-04-25 2021-09-10 北京交通大学 一种呼吸道合胞病毒融合前f蛋白及其应用
US20230201334A1 (en) 2019-07-24 2023-06-29 Glaxosmithkline Biologicals Sa Modified human cytomegalovirus proteins
CN114502572A (zh) 2019-09-04 2022-05-13 华盛顿大学 展示副粘病毒和/或肺炎病毒f蛋白的自组装蛋白纳米结构及其用途
WO2021132379A1 (ja) * 2019-12-23 2021-07-01 田辺三菱製薬株式会社 変異型ｒｓｖ ｆタンパク質及びその利用
TWI810589B (zh) * 2020-06-21 2023-08-01 美商輝瑞股份有限公司 人巨細胞病毒糖蛋白Ｂ（ｇＢ）多肽
CN112899214B (zh) * 2020-07-07 2023-08-04 湖南师范大学 废弃鱼鳞在制备各向异性基底中的应用
JP2022023813A (ja) 2020-07-27 2022-02-08 ファイザー・インク 組換え生産されたｒｓｖタンパク質の精製方法における陰イオン交換クロマトグラフィー用洗浄溶液の改良
JP2022023814A (ja) 2020-07-27 2022-02-08 ファイザー・インク 組換え生産された三量体型のｒｓｖタンパク質の精製方法
CN112226444B (zh) * 2020-08-25 2022-11-04 北京交通大学 呼吸道合胞病毒全长融合前融合糖蛋白核苷酸序列、重组腺病毒载体及其应用产品
JP2022060169A (ja) 2020-10-02 2022-04-14 ファイザー・インク Ｒｓｖ ｆタンパク質生産のための細胞培養工程
CN114685676B (zh) * 2020-12-28 2024-02-13 兰州生物制品研究所有限责任公司 一种重组蛋白及其表达方法、纯化方法及用途
US20240228548A9 (en) * 2021-02-19 2024-07-11 Janssen Vaccines & Prevention B.V. Stabilized pre-fusion rsv fb antigens
WO2022234405A1 (en) 2021-05-03 2022-11-10 Pfizer Inc. Vaccination against bacterial and betacoronavirus infections
WO2023144665A1 (en) 2022-01-28 2023-08-03 Glaxosmithkline Biologicals Sa Modified human cytomegalovirus proteins
CN117715923A (zh) * 2022-04-29 2024-03-15 北京新合睿恩生物医疗科技有限公司 Rsv f蛋白突变体及其应用
WO2024041773A1 (en) * 2022-08-22 2024-02-29 Glaxosmithkline Biologicals Sa Rsv-f proteins
CN116003536A (zh) * 2022-09-23 2023-04-25 暨南大学 呼吸道合胞病毒融合前f蛋白突变体及其应用
WO2024069420A2 (en) 2022-09-29 2024-04-04 Pfizer Inc. Immunogenic compositions comprising an rsv f protein trimer
WO2024078597A1 (en) * 2022-10-13 2024-04-18 Rvac Medicines (Us) , Inc. Rsv f protein variants and uses thereof
WO2024089633A1 (en) 2022-10-27 2024-05-02 Pfizer Inc. Rna molecules encoding rsv-f and vaccines containing them
WO2024089634A1 (en) 2022-10-27 2024-05-02 Pfizer Inc. Immunogenic compositions against influenza and rsv
WO2024093554A1 (zh) * 2022-11-04 2024-05-10 北京康乐卫士生物技术股份有限公司 针对rsv的重组亚单位疫苗及其应用
CN116284266B (zh) * 2022-11-21 2024-01-19 怡道生物科技(苏州)有限公司 突变型呼吸道合胞病毒融合前f蛋白及其应用
WO2024127181A1 (en) 2022-12-11 2024-06-20 Pfizer Inc. Immunogenic compositions against influenza and rsv
CN117487823A (zh) * 2023-09-28 2024-02-02 怡道生物科技(苏州)有限公司 呼吸道合胞体病毒mRNA疫苗及其制备方法和应用
CN117304278B (zh) * 2023-11-28 2024-04-16 江苏瑞科生物技术股份有限公司 一种重组rsv f蛋白及其应用
CN117304279B (zh) * 2023-11-28 2024-04-16 江苏瑞科生物技术股份有限公司 一种重组rsv f蛋白及其应用
CN117304280B (zh) * 2023-11-28 2024-04-16 江苏瑞科生物技术股份有限公司 一种重组rsv f蛋白及其应用
CN117567652B (zh) * 2024-01-19 2024-05-14 北京安百胜生物科技有限公司 一种重组呼吸道合胞病毒颗粒抗原
CN117586359A (zh) * 2024-01-19 2024-02-23 北京安百胜生物科技有限公司 一种具有免疫原性的呼吸道合胞病毒（rsv）多肽
CN117645655B (zh) * 2024-01-26 2024-05-24 普大生物科技(泰州)有限公司 一种肺炎球菌多糖-rsv重组蛋白结合疫苗及其制备方法
CN117777251B (zh) * 2024-02-27 2024-06-04 普大生物科技(泰州)有限公司 一种rsv纳米颗粒疫苗及其制备方法

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
NZ230747A (en) 1988-09-30 1992-05-26 Bror Morein Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina
JPH0832638B2 (ja) 1989-05-25 1996-03-29 カイロン コーポレイション サブミクロン油滴乳剤を含んで成るアジュバント製剤
US5340740A (en) 1992-05-15 1994-08-23 North Carolina State University Method of producing an avian embryonic stem cell culture and the avian embryonic stem cell culture produced by the process
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
FR2726003B1 (fr) 1994-10-21 2002-10-18 Agronomique Inst Nat Rech Milieu de culture de cellules embryonnaires totipotentes aviaires, procede de culture de ces cellules, et cellules embryonnaires totipotentes aviaires
SE0202110D0 (sv) 2002-07-05 2002-07-05 Isconova Ab Iscom preparation and use thereof
SE0301998D0 (sv) 2003-07-07 2003-07-07 Isconova Ab Quil A fraction with low toxicity and use thereof
TW200636064A (en) 2004-10-28 2006-10-16 Centocor Inc Anti-respiratory syncytial virus antibodies, antigens and uses thereof
WO2008114149A2 (en) 2007-03-21 2008-09-25 Id Biomedical Corporation Of Quebec Chimeric antigens
EP1997830A1 (en) 2007-06-01 2008-12-03 AIMM Therapeutics B.V. RSV specific binding molecules and means for producing them
WO2008154456A2 (en) 2007-06-06 2008-12-18 Nationwide Children's Hospital, Inc. Methods and compositions relating to viral fusion proteins
SG188813A1 (en) * 2007-12-24 2013-04-30 Id Biomedical Corp Quebec Recombinant rsv antigens
CN102131830A (zh) 2008-07-18 2011-07-20 魁北克益得生物医学公司 嵌合呼吸道合胞病毒多肽抗原
US8580270B2 (en) 2008-09-30 2013-11-12 University Of Massachusetts Respiratory synctial virus (RSV) sequences for protein expression and vaccines
AU2009333484B2 (en) 2008-12-09 2014-12-11 Novavax, Inc. Modified RSV F proteins and methods of their use
KR20120093811A (ko) * 2009-06-24 2012-08-23 아이디 바이오메디컬 코포레이션 오브 퀘벡 백신
AU2010264688A1 (en) * 2009-06-24 2012-01-19 Glaxosmithkline Biologicals S.A. Recombinant RSV antigens
HRP20220756T1 (hr) 2009-07-15 2022-09-02 Glaxosmithkline Biologicals S.A. Proteinski pripravci rsv f i postupci za izradu istih
NZ599148A (en) 2009-10-06 2014-08-29 Medimmune Ltd Rsv-specific binding molecule
WO2012021730A2 (en) * 2010-08-11 2012-02-16 Genvec, Inc. Respiratory syncytial virus (rsv) vaccine
EP4159232A1 (en) 2011-01-26 2023-04-05 GlaxoSmithKline Biologicals S.A. Rsv immunization regimen
RS56748B1 (sr) 2011-05-13 2018-03-30 Glaxosmithkline Biologicals Sa Pre-fuzioni rsv f antigeni
ES2395677B1 (es) 2011-07-29 2013-12-26 Instituto De Salud Carlos Iii Proteína F del VRSH en conformación pre-fusión estabilizada y anticuerpos neutralizantes específicos frente a la misma.
CA2849471A1 (en) 2011-09-30 2013-04-04 Novavax, Inc. Recombinant nanoparticle rsv f vaccine for respiratory syncytial virus
AU2013237424B2 (en) 2012-03-22 2017-07-06 Janssen Vaccines & Prevention B.V. Vaccine against RSV
EP2922570A1 (en) 2012-11-20 2015-09-30 GlaxoSmithKline Biologicals SA Rsv f prefusion trimers
RU2761631C2 (ru) * 2013-03-13 2021-12-13 Дзе Юнайтед Стэйтс Оф Америка, Эс Репрезентед Бай Дзе Секретэри, Департмент Оф Хелт Энд Хьюман Сервисиз Белки rsv в предшествующей слиянию конформации и их применение
US9738689B2 (en) * 2013-03-13 2017-08-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Prefusion RSV F proteins and their use
TR201902513T4 (tr) 2013-04-25 2019-03-21 Janssen Vaccines & Prevention Bv Stabilize edilmiş çözünebilir prefüzyon RSV F polipeptitleri.
MY171210A (en) 2013-06-17 2019-10-02 Janssen Vaccines & Prevention Bv Stabilized soluble pre-fusion rsv f polypeptides
JP6685903B2 (ja) 2013-07-25 2020-04-22 アバター・メディカル・エルエルシー 立体構造的に安定化されたｒｓｖ融合前ｆタンパク質
US20150166610A1 (en) * 2013-10-14 2015-06-18 Glaxosmithkline Biologicals, S.A. Recombinant rsv antigens
EP2974739A1 (en) * 2014-07-15 2016-01-20 Novartis AG RSVF trimerization domains
CN108348593B (zh) * 2015-08-31 2022-08-16 泰克诺瓦克斯股份有限公司 基于人呼吸道合胞病毒(hrsv)病毒样颗粒(vlps)的疫苗
US10496141B2 (en) 2016-03-17 2019-12-03 Qualcomm Incorporated System and method for intelligent thermal management in a system on a chip having a heterogeneous cluster architecture

Also Published As

Publication number Publication date
RU2723039C2 (ru) 2020-06-08
AU2021202522A1 (en) 2021-05-27
KR102505354B1 (ko) 2023-03-02
US20170182151A1 (en) 2017-06-29
US10238732B2 (en) 2019-03-26
IL311990A (en) 2024-06-01
KR20230035429A (ko) 2023-03-13
JP7212198B2 (ja) 2023-01-24
MX2021007070A (es) 2021-08-11
RU2018122823A3 (es) 2020-01-23
AU2021202522C1 (en) 2023-11-23
KR20180081614A (ko) 2018-07-16
TWI838685B (zh) 2024-04-11
RU2020115606A (ru) 2020-06-29
TWI756828B (zh) 2022-03-01
US9950058B2 (en) 2018-04-24
US10821171B2 (en) 2020-11-03
IL260203A (en) 2018-07-31
AU2021202522B2 (en) 2023-05-11
CO2018006301A2 (es) 2018-07-10
JP7193522B2 (ja) 2022-12-20
PE20181354A1 (es) 2018-08-22
WO2017109629A1 (en) 2017-06-29
AU2016379097B2 (en) 2019-08-22
AU2016379097C1 (en) 2021-04-08
TW201920238A (zh) 2019-06-01
EP3393512A1 (en) 2018-10-31
US20180177864A1 (en) 2018-06-28
AU2019210579A1 (en) 2019-08-22
AU2016379097A1 (en) 2018-06-07
JP2021061845A (ja) 2021-04-22
MX2018007622A (es) 2018-11-14
SA518391839B1 (ar) 2023-10-22
US20210023200A1 (en) 2021-01-28
SG10202001389PA (en) 2020-04-29
SG11201804148TA (en) 2018-07-30
JP2019511998A (ja) 2019-05-09
RU2018122823A (ru) 2020-01-23
TWI707866B (zh) 2020-10-21
TW201726709A (zh) 2017-08-01
TWI656130B (zh) 2019-04-11
CA2952131C (en) 2023-12-05
JP2022185022A (ja) 2022-12-13
JP2023015335A (ja) 2023-01-31
PE20232039A1 (es) 2023-12-21
KR20200090932A (ko) 2020-07-29
AU2019210579B2 (en) 2021-01-28
CA2952131A1 (en) 2017-06-23
US20190125861A1 (en) 2019-05-02
CN108738312A (zh) 2018-11-02
KR102136678B1 (ko) 2020-07-22
BR112018010805A2 (pt) 2018-11-27
AU2023214269A1 (en) 2023-10-12
PH12018501355A1 (en) 2019-02-18
US20230218738A1 (en) 2023-07-13
CA3217696A1 (en) 2017-06-23
TW202216738A (zh) 2022-05-01
IL260203B1 (en) 2024-05-01
JP6817307B2 (ja) 2021-01-20
RU2020115606A3 (es) 2020-11-23
TW202124414A (zh) 2021-07-01

Similar Documents

Publication Publication Date Title
PE20240817A1 (es) Mutantes de proteina f de rsv
CL2019001000A1 (es) Proteínas de fusión fc heterodiméricas il15/il15ralfa
CO2018012096A2 (es) Proteínas de fusión gdf15 y usos de estas
EA202090090A1 (ru) Включение неприродных нуклеотидов и способы с ними
CO2018003863A2 (es) Anticuerpos anti-vegf
CO2019002609A2 (es) Proteínas de unión recombinantes y sus usos
BR112017007816A2 (pt) composições farmacêuticas compreendendo variantes de peptídeos e métodos de uso das mesmas
PE20161442A1 (es) Proteinas quimericas tipo fosfatasa alcalina
PH12019500209A1 (en) Methods and compositions for gene expression in plants
EA201691111A1 (ru) Химерные белки фактора viii и их применение
EA201491051A1 (ru) Вакцины против вируса гриппа и их применения
BR112017015833A2 (pt) compostos anti-senescência e usos dos mesmos
EA201791238A1 (ru) Способы и композиции, в которых используются варианты полипептидов klotho
MX371033B (es) Productos farmacéuticos mejorados de péptido para resistencia a la insulina.
MX371403B (es) Moleculas de andamiaje a base de fibronectina estabilizada.
CO6210831A2 (es) Nuevas proteinas h5 moleculas de acido nucleico y vectores que las codifican y su uso medicinal
WO2016130628A8 (en) Griffithsin mutants
EA202091769A1 (ru) Вакцины против вируса гриппа и пути их применения
EA201891141A1 (ru) Новые антиангиогенные слитые полипептиды
AR101555A1 (es) ANTICUERPOS DIRIGIDOS AL RECEPTOR IIB DE Fc g Y AL RECEPTOR DE Fc e
EA201691691A1 (ru) Белки слияния tatk-cdkl5, их композиции, составы и применение
EA202091567A1 (ru) Химерные белки мти
PH12020550099A1 (en) Fusion protein comprising an fgf-18 moiety
EA202191123A1 (ru) Миниатюризированные дистрофины и их применения
BR112017014737A2 (pt) formulação de peptídeos inibidores de mk2